Poxel to Report Full Year 2019 Financial Results and Host Conference Call on March 26, 2020 Mar 4, 2020
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2019 and Provides Corporate Update Feb 12, 2020
Poxel Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd Annual Global NASH Congress Feb 12, 2020
Poxel and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results from TIMES 2 Trial of Imeglimin for the Treatment of Type 2 Diabetes in Japan and Successful Completion of the Pivotal TIMES Clinical Development Program Dec 20, 2019
Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japan Nov 26, 2019
